Status:
COMPLETED
Gabapentin Treatment of Cannabis Dependence
Lead Sponsor:
The Scripps Research Institute
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
Detailed Description
This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and research assessments occ...
Eligibility Criteria
Inclusion
- Males or females age 18-65 with cannabis dependence
- Meets DSM-IV-TR criteria for Cannabis Dependence
- Smoked marijuana at least once a week in the 90 days prior to study participation
- Willing to attend 12 weekly study visits and 1 follow-up visit
Exclusion
- Currently meets DSM-IV-TR criteria for dependence on illicit substances other than cannabis
- Significant medical disorders that will increase potential risk or interfere with study participation
- Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
- Treatment with an investigational drug in the last month
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00395044
Start Date
August 1 2006
End Date
July 1 2008
Last Update
February 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Scripps Research Institute
La Jolla, California, United States, 92037